The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes
- First Online:
- Cite this article as:
- Richardson, S.J., Willcox, A., Bone, A.J. et al. Diabetologia (2009) 52: 1143. doi:10.1007/s00125-009-1276-0
- 1.8k Downloads
Evidence that the beta cells of human patients with type 1 diabetes can be infected with enterovirus is accumulating, but it remains unclear whether such infections occur at high frequency and are important in the disease process. We have now assessed the prevalence of enteroviral capsid protein vp1 (vp1) staining in a large cohort of autopsy pancreases of recent-onset type 1 diabetic patients and a range of controls.
Serial sections of paraffin-embedded pancreatic autopsy samples from 72 recent-onset type 1 diabetes patients and up to 161 controls were immunostained for insulin, glucagon, vp1, double-stranded RNA activated protein kinase R (PKR) and MHC class I.
vp1-immunopositive cells were detected in multiple islets of 44 out of 72 young recent-onset type 1 diabetic patients, compared with a total of only three islets in three out of 50 neonatal and paediatric normal controls. vp1 staining was restricted to insulin-containing beta cells. Among the control pancreases, vp1 immunopositivity was also observed in some islets from ten out of 25 type 2 diabetic patients. A strong correlation was established between islet cell vp1 positivity and PKR production in insulin-containing islets of both type 1 and type 2 diabetic patients, consistent with a persistent viral infection of the islets.
Immunoreactive vp1 is commonly found in the islets of recent-onset type 1 diabetes patients, but only rarely in normal paediatric controls. vp1 immunostaining was also observed in some islets of type 2 diabetes patients, suggesting that the phenomenon is not restricted to type 1 diabetes patients.
KeywordsBeta cells Enterovirus Environmental triggers Insulitis Islets of Langerhans MHC PKR Type 1 diabetes Type 2 diabetes
Coxsackie B enterovirus
Double-stranded RNA activated protein kinase R
Enteroviral capsid protein vp1
Enteroviral infection has long been implicated in triggering autoimmunity, islet inflammation (insulitis) and beta cell death in human type 1 diabetes. Much of the evidence is circumstantial  but includes observations that antibodies against common Coxsackie B enteroviruses (CVB) and enteroviral RNA occur more frequently in the circulation of recent-onset type 1 diabetes patients than in controls [2, 3, 4, 5, 6, 7, 8, 9, 10].
More direct support for a viral aetiology has come from the demonstration that a strain of CVB4, isolated from the pancreas of a recent-onset type 1 diabetic patient, was capable of inducing diabetes in mice . In addition, the presence of enteroviral RNA was revealed by in situ hybridisation in the islets of four recent-onset type 1 diabetes cases  and the enteroviral capsid protein vp1, was detected in the beta cells of two of five patients with type 1 diabetes, and in a sixth diabetic patient who had received a recent pancreatic transplant . Electron microscopic analysis revealed the presence of virus particles within the islet beta cells of vp1-positive cases, and a strain of CVB4 was isolated from the pancreas of one patient. This was capable of infecting normal human islets in vitro, resulting in their functional impairment .
Enteroviral infection can result in the production of double-stranded RNA (dsRNA) within cells  and dsRNA-activated protein kinase R (PKR) was upregulated in islets infected by CVB5 in vitro . Similarly, CVB-infected islets produced IFN-α in vitro  and this has been associated with hyperexpression of class I MHC .
In view of these findings, we considered it important to establish the prevalence of immunoreactive vp1 staining in the islets of a large cohort of recent-onset type 1 diabetes cases and in a wide range of relevant controls. We have also established whether an antiviral response is mounted in the islets of these patients by immunostaining for PKR. Finally, we have assessed whether vp1 staining occurs independently of insulitis.
Formalin-fixed, paraffin-embedded pancreatic autopsy tissue from 72 patients with recent-onset type 1 diabetes mellitus, whose pancreatic histology has been described previously  was used, with ethical permission. The cases were from various hospitals and had been fixed in buffered formalin, formol saline, formol saline with added mercuric chloride, or Bouin’s fixative, with no standardisation of fixation time. The cohort consisted of 41 female and 31 male patients with a mean age of 12.65 ± 1.1 years (range 1–42 years) and a mean time since diagnosis of 8.2 ± 4.1 months (range 0–6 years). Control autopsy tissues, fixed in a similar variety of fixatives, were five culture-proven Coxsackie virus-infected neonatal pancreases and hearts; 11 normal neonatal pancreases (<1 month); three normal neonatal hearts; 39 normal paediatric pancreases (age range 6 weeks–17 years); 11 pancreases from cystic fibrosis patients with a mean age of 8.1 ± 1.7 years (age range 2–19 years); 69 normal adult pancreases and 25 pancreases from adult patients with type 2 diabetes.
Analysis of islet staining with three anti-enteroviral antisera in 11 cases of type 1 diabetes
Number of ICIs
Number of ICIs stained by:
Any two antisera
Primary antibodies were applied for 30 min at room temperature (except for anti-pan-enterovirus [9D5] and anti-PKR, which were incubated overnight at 4°C) and a Dako REAL Envision Detection System used for antigen detection. Some slides were processed in the absence of primary antibody or with isotype control antisera to confirm the specificity of labelling. Slides were analysed by light microscopy.
To determine the islet cell subtypes infected by enterovirus, double immunofluorescence staining was performed. Anti-insulin, anti-glucagon and anti-vp1 reactivities were detected using an Alexa Fluor 488-conjugated anti-guinea pig antibody, an Alexa Fluor 488-conjugated anti-rabbit antibody and an Alexa Fluor 568-conjugated anti-mouse antibody, respectively (Invitrogen, Paisley, UK). Sections were mounted using Vectashield medium (Vector Labs, Burlingame, CA, USA) and were observed using a Zeiss LSM510 Meta confocal microscope (Welwyn Garden City, UK).
Results are shown as means ± SEM. Statistical analysis was performed either by a χ2 test or Student’s t test, as appropriate.
vp1 staining in the islets of recent-onset type 1 diabetic patients
Probing of the pancreases from our cohort of type 1 diabetes patients with the Dako anti-vp1 antibody revealed the presence of small numbers of intensely stained cells in multiple islets from the majority of cases (Fig. 1b, c). These immunopositive islet cells were readily distinguishable from the surrounding unstained endocrine cells (which formed the majority in all cases), suggesting that the antibody did not label an endogenous islet cell antigen. To facilitate quantitative analysis, a case was deemed positive for vp1 when at least one intensely stained endocrine cell was present in an islet within any given section. Using this criterion, 44 of the 72 (61%) recent-onset type 1 diabetes cases were positive for enteroviral vp1 antigen (Fig. 1g) and most contained multiple immunopositive cells in a range of islets. Comparison of the age and sex of the patients failed to reveal any significant differences between the vp1-positive and vp1-negative cases. However, the duration of diabetes tended to be lower in the vp1-positive group (2.32 ± 0.8 months vs 16.5 ± 8.0 months; p = 0.06).
Occasional islet cell vp1 immunopositivity was detected in the pancreases of three of 39 (7.7%) non-diabetic paediatric cases (Fig. 1e, g) but this amounted to a total of only four endocrine cells among the entire islet population examined. This was significantly lower than that observed in the patients with type 1 diabetes (χ2 = 29.71, p < 0.001). A series of 11 paediatric cystic fibrosis pancreases was also examined for vp1 immunopositivity to determine whether the viral protein is found commonly in patients with another pancreatic inflammatory disease. Of these, two contained multiple vp1-positive islets similar to those seen in the type 1 diabetes patients (not shown). Importantly, subsequent examination of the case histories of these patients revealed that the two with vp1 immunopositivity in the islets also had diabetes. None of the vp1-negative cystic fibrosis cases had diabetes.
vp1 immunostaining is restricted to insulin-containing islets (ICIs)
The presence of CD45+ immune cells was also examined to determine whether a relationship existed between vp1 immunopositivity and the extent of insulitis in type 1 diabetes patients. A total of 200 vp1-positive ICIs were studied (from seven patients) and 123 (61.5%) of these showed no evidence of inflammation (i.e. they were negative for CD45).
Verification of islet vp1 staining with other enteroviral antisera
Correlation between islet vp1 staining and additional markers of viral infection
vp1 staining in sections of pancreases from type 2 diabetic patients and from non-diabetic adults
A more detailed comparison of the frequency of vp1-positive islets in ten type 1 and six type 2 diabetic pancreases as well as seven non-diabetic adult pancreases was performed (Fig. 6f). The cases were chosen at random among pancreases which had vp1-positive islets. Seventy of 251 (27.9%) islets contained vp1-positive endocrine cells in the six type 2 diabetes pancreas sections studied, whereas only 15 of 210 (7.1%) islets from seven normal adult pancreases contained equivalent cells (Fig. 6f; χ2 = 32.81, p < 0.001). This compared with 269 of 342 (78.7%) vp1-positive ICIs in the ten type 1 diabetes cases studied in detail (χ2 = 152.31, p < 0.001; vs type 2 diabetes). In the islets of patients with type 2 diabetes islets that were vp1-positive, PKR immunopositivity was also often detected (Figs 5c and 6g). Hyperexpression of MHC-I was not seen in any islet from type 2 diabetes patients (Fig. 5c), nor in non-diabetic adult pancreases.
Finally, in some cases, focal pancreatic centroacinar cells in the exocrine tissue and some smooth muscle cells in vein walls were stained positively by the Dako anti-vp1 serum (Fig. 6c, d). Such staining was also seen, but much less frequently, in the neonatal and paediatric pancreases of both diabetic and non-diabetic patients, and it was never observed with the Kdf antiserum.
Circumstantial evidence has implicated enteroviral infection in the aetiology of type 1 diabetes but direct support for the hypothesis that islet cell enterovirus infection is a common occurrence in the disease has been more difficult to obtain . However, it was recently reported that vp1 was detectable in a range of beta cells in two of five recent-onset type 1 diabetic patients and in another diabetic patient who had received a pancreatic transplant, but not in 26 non-diabetic controls . In order to verify and extend this finding, we have analysed the prevalence of pancreatic islet vp1 immunopositivity in 72 recent-onset type 1 diabetic patients and in a range of controls. The results reveal a prevalence of islet vp1 immunopositivity of ~61% in type 1 diabetic patients, with almost no equivalent staining in the pancreases of neonatal and paediatric non-diabetic controls. Double immunofluorescence studies showed that vp1 staining was confined to beta cells. Thus, the proposal that vp1 immunopositivity may be common in the insulin-secreting cells of type 1 diabetic patients is supported by this more extensive analysis.
An important consideration is the identity of the antigen labelled by the Dako vp1 antiserum. Previously, the specificity of the Dako vp1 antiserum has been assessed by comparing immunohistochemical and enteroviral RNA detection techniques. For example, in a study of heart biopsies of 70 patients with dilated cardiomyopathy, enteroviral RT-PCR testing was positive in 25 samples. Seventeen of these had focal staining of cardiac myocytes by Dako vp1 antiserum, while all of the RT-PCR-negative samples were vp1-negative on immunohistochemistry. All 45 normal control hearts were negative with both techniques . Additionally, RT-PCR for enterovirus was positive in salivary gland biopsies in seven of eight patients with primary Sjogren’s syndrome but not in 16 normal salivary glands. Ductal, acinar and infiltrating inflammatory cells stained positively with Dako anti-vp1 in the Sjogren’s syndrome cases but not in the controls .
We verified that the Dako vp1 antibody labelled human cardiac myocytes in neonates infected with a number of different CVB in vivo, whereas non-infected neonatal heart was immunonegative. However, in common with others [19, 23] we also noted that the Dako antiserum can, under certain conditions, label tissues in which vp1 production is not expected. In particular, our preliminary work revealed that, when applied to formalin-fixed, paraffin-embedded sections of Coxsackie-infected neonatal mouse organs, this antibody stained some tissues which were reported to be negative for viral RNA by in situ hybridisation . These included smooth muscle, bone, dental and hair follicle epithelium, pancreatic duct and centroacinar cells. Moreover, these tissues were also stained by the antibody in uninfected neonatal mice. Thus, while it is clear that the Dako antibody is a sensitive agent for labelling enteroviral vp1 in a range of tissues in mouse and man, it is also evident that it can label non-infected cells, including, in the pancreas, vascular smooth muscle and centroacinar cells. However, it should be emphasised that in uninfected neonatal mice and neonatal children the antibody did not stain pancreatic endocrine cells. Thus, in the context of islets of Langerhans, the Dako antibody stained endocrine cells only in control tissues known to be infected by virus.
Polyclonal antisera raised against enteroviruses have been shown to cross react with heat shock protein (hsp)-60  and the tyrosine phosphatase, IA-2 . However, it seems unlikely that the Dako vp-1 antiserum recognised either of these proteins in the beta cells in this study. IA-2 is present in alpha cells as well as beta cells, while the vp1 staining was seen in a minority of beta cells, but not alpha cells. The expression of hsp-60 has been studied in these diabetic samples before  and there was no equivalent staining of occasional beta cells as described here for vp1.
Because of the potential for non-specific immunoreactions with the Dako antiserum and possible doubts about the origin of the virus isolated previously [13, 28] we used two additional antisera raised against enteroviral proteins to analyse the presence of enterovirus in sections of pancreas. With each of these antisera, specific enteroviral immunopositivity was first demonstrated in infected neonatal human hearts. Both antisera stained endocrine cells in ICIs, which correlated with immunopositivity detected with Dako anti-vp1 in some, but not all, type 1 diabetic patients tested.
In an earlier study  two additional techniques were used to verify that vp1 immunostaining in diabetic islets represented virus infection. First, virus particles were observed by electron microscopy, confined to beta cells, in the same cases as had demonstrable vp1. Second, a strain of CVB4 was isolated from one of the pancreas samples and shown to be capable of infecting normal human islets in vitro, leading to impaired glucose-stimulated insulin secretion . While this evidence appears persuasive, others  have cast doubt on the origin of the virus strain, by suggesting that the reported RNA sequence analysis implies possible contamination with a laboratory strain.
Since most of the previous studies [13, 21, 22] were conducted using fresh biopsy tissues, or tissues removed at the time of organ donation, the authors were able to employ electron microscopy, RT-PCR or in situ hybridisation techniques to confirm the validity of the vp1 staining. These options were not open to us since the pancreatic material from patients with diabetes in the present study was collected almost entirely retrospectively from autopsies performed hours after the death of patients. In previous work  attempts were made to detect enteroviral RNA by in situ hybridisation in this collection and no evidence of infection was found. The poor quality of RNA in formalin-fixed, paraffin-embedded autopsy pancreas, probably the result of early RNA degradation in a tissue rich in RNAse, was exemplified in that study by the fact that mRNA for insulin could be detected by in situ hybridisation in only 29 of the 75 pancreases studied, even though all had insulin-containing beta cells as shown by immunohistochemistry. In support of this, others also failed to detect viral RNA by in situ hybridisation in an autopsy pancreas where evidence of viral protein production was detected by immunohistochemistry . Thus no attempt was made in the present study to repeat the search for enteroviral RNA by in situ hybridisation or RT-PCR. Rather, we looked at the production of another protein that is upregulated in response to enteroviral infection, PKR , and found a strong concordance between PKR immunopositivity and that for vp1 in the islets of both type 1 and type 2 diabetic patients. This is arguably the best evidence in the present study that detection of vp1 by the Dako antibody in beta cells is indicative of a persistent enteroviral infection.
While staining of vp1 correlated with PKR immunostaining in the islets of patients with type 1 diabetes it was not seen in many of the ICIs where there was hyperexpression of class I MHC on endocrine cells. This latter phenomenon is intimately associated with IFN-α production by beta cells  and is unique to type 1 diabetes . Thus, vp1 staining of beta cells does not appear to be directly associated with secretion of IFN-α and it is unclear why IFN-α is produced by beta cells in those islets which hyperexpress class I MHC  but have no demonstrable viral capsid protein.
In experimental acute enteroviral myocarditis in mice, viral capsid protein was most easily detectable by immunohistochemistry under conditions where there was an excess of positive- over negative-strand viral RNA within infected cells. By contrast, when the infection continued into a chronic phase, the number of positive and negative enteroviral RNA strands per cell became equivalent and capsid protein was less readily demonstrable . On this basis, it is conceivable that a molecular form of virus that is not readily detectable by immunohistochemistry for vp1, may exist as a chronic infection in many of the beta cells in type 1 diabetes and that, occasionally, production of the whole virus increases, leading to capsid protein synthesis in a small number of beta cells. If this hypothesis is correct, then our results imply that the molecular form of virus detectable by vp1 immunostaining is also the form that most potently induces PKR production, whereas IFN-α may be induced by both molecular forms.
Extending the current analysis revealed that, surprisingly, 40% of adult type 2 diabetes cases displayed focal staining for vp1 in their islets. The staining pattern was indistinguishable from that seen in the islets of patients with type 1 diabetes (although it occurred much less frequently in type 2 diabetes), which might suggest that immunopositivity for vp1 occurs as a consequence of diabetes. Alternatively, enteroviral infection could play an important role in the pathology of beta cell loss and malfunction in both type 1 and type 2 diabetes.
The latter proposition is consistent with evidence that type 2 diabetes may be associated with islet cell inflammation , although it must also be noted that there is no induction of autoimmunity in type 2 diabetes. Nevertheless, our present finding of production of PKR in consort with vp1 in the islets of patients with type 2 diabetes is consistent with an active response by infected endocrine cells to the presence of virus in this disease. Since non-cytopathic infection of beta cells by enterovirus leads to decreased glucose-induced insulin secretion in vitro  it is conceivable that, in a person with obesity and increased insulin resistance, in whom the demand for insulin is raised, such an infection may contribute to beta cell dysfunction and the development of type 2 diabetes, even if not associated with autoimmunity. Our findings could also suggest a similar role for enterovirus infection in precipitating clinical diabetes in some patients with cystic fibrosis.
vp1 staining in islets was found in ~10% of non-diabetic controls of all ages. This is consistent with studies showing that 4–5% of normal children had enteroviral RNA in their serum [4, 7, 8] and 11.8% had enteroviral RNA present in faecal samples [34, 35]. Since a range of enteroviruses can infect human islets in vitro [12, 36, 37] it is possible that the pancreas is frequently colonised during an enteroviral infection.
Overall, our results are consistent with the hypothesis that enteroviral infection of beta cells at a young age, in patients with a genetic predisposition to type 1 diabetes, might precipitate autoimmunity. The islet reaction to that infection would include production of PKR, secretion of IFN-α and abnormal production of MHC molecules, leading to the type 1 form of the disease. Infection by a similar virus, in a person with a different genetic background, might be associated with PKR production, but if it did not precipitate IFN-α production by beta cells, or abnormalities of islet MHC expression in islets, this infection would not be associated with autoimmunity, and in the great majority of patients would lead to no clinical disease. However, in patients with an already compromised metabolic situation, as a result of insulin resistance, it may contribute to the development of type 2 diabetes. Further studies, including viral RNA detection techniques on fresh, organ-donation, pancreas samples from patients with recent-onset disease, are indicated to confirm the presence and identity of enterovirus strains causing diabetes.
We thank Diabetes UK, the Juvenile Diabetes Research Foundation and a Coordinated Action of the European Union (TONECA) for financial support of this study. We also thank R. Kandolf (Tübingen, Germany) and J. Neefjes (Amsterdam) for their kind gifts of vp1 and MHC-I antibodies used in this work and D. Hilton (Derriford Hospital, Plymouth, UK) for paraffin-embedded Coxsackie-infected neonatal mouse sections.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.